Q3 2024 Earnings Call Transcript November 12, 2024 Operator: Welcome to Natera’s 2024 Third Quarter Financial Results ...

They also highlighted the recently initiated Phase 1/2 trial of GEN-1057 in malignant solid tumors. At the ESMO conference, ...

Good morning and welcome to Agenus' third quarter 2024 conference call and webcast. All participants will be in a listen-only ...

I would now like to turn the conference over to Alexa buffet from corporate communications ... The initial data we presented at ESMO GI in 2024 just a few months ago from the Cornell study highlights ...

Primary PFS and interim OS results from TROPION-Lung01 were presented at the ESMO 2023 Congress. Final OS results were presented at IASLC 2024 World Conference on Lung Cancer hosted by the ...

Merus’ zenocutuzumab is nearing FDA approval, and petosemtamab shows promise. Learn why MRUS stock could rise as the company ...

For BNT113, our mRNA vaccine candidate against HPV16 positive cancer, we presented data from two trials at the ESMO conference. One data set was from the safety run-in cohort of our potentially ...

CET/CEST The issuer is solely responsible for the content of this announcement. CureVac to Present at the 12th Interna ...

Net financial result for the three and nine months ended September 30, 2024, amounted to €2.2 million and €8.0 million, or a decrease of €3.1 million and €4.7 million, from €5.3 million and €12.7 ...

Issuer: CureVac / Key word (s): Conference CureVac to Present at the 12th International mRNA Health Conference 04.11.2024 / 13:00 CET/CEST The issuer is solely responsible for the content of this ...

Welcome to BioNTech's third quarter 2024 earnings call. I would like to hand the call over to Michael Horowicz Director, Investor Relations. Please go ahead.

About Aptevo Therapeutics Inc. Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel immuno-oncology therapies for the treatment of cancer. Aptevo is seeking ...